Overview

Trial of JYB1904 in Patients With Allergic Asthma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.
Phase:
PHASE2
Details
Lead Sponsor:
Jemincare
Treatments:
Omalizumab